Pharmacoeconomic efficacy of moxifloxacin sequential therapy for community-acquired pneumonia in elderly patients

Objective To evaluate pharmacoeconomic efficacy of two different dosage regimens of moxifloxacin in the treatment of community acquired pneumonia in elderly patients.Method A total of 80 patients were randomly enrolled into 2 groups:moxifloxacin injection followed by tablet(sequential group) and moxifloxacin injection group(control group).Moxifloxacin was administered by intravenous infusion,400 mg/250 ml once daily for 11 days in control group(n=40).In sequential group(n=40),moxifloxacin was given by intravenous infusion 400 mg/250 ml,once daily for 5 days,followed by oral administration at the same dose.The total treatment duration was also 11 days.After the end of therapy,to the clinical efficacy and pharmacoeconomic efficacy were evaluation.Results For sequential group vs.control group,the cute rate was 57.5% vs 62.5%(P0.05),the effective rate was 90.0% vs 92.5%(P0.05),and the incidence of ADRs was 7.5% vs 10%(P0.05).The cost-effectiveness of sequential group(2 000.0) was lower than control group(3864.9).Conclusion Moxifloxacin sequential therapy is efficacious,safety and cost-effective for community-acquired pneumonia in elderly patients.